• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Radiol . Peripheral and central smell regions in COVID-19 positive patients: an MRI evaluation

tetano

Editor, Senior Moderator
Acta Radiol


. 2021 Jul 20;2841851211034043.
doi: 10.1177/02841851211034043. Online ahead of print.
Peripheral and central smell regions in COVID-19 positive patients: an MRI evaluation


Veysel Burulday[SUP] 1 [/SUP], Merve Sefa Sayar[SUP] 2 [/SUP], Nuray Bayar Muluk[SUP] 3 [/SUP]



Affiliations

Abstract

Background: Coronaviruses may lead to invasion of the central nervous system.
Purpose: To investigate the effects of COVID-19 infection on smell using cranial magnetic resonance imaging (MRI).
Material and methods: Cranial MRI scans of 23 patients with COVID-19 (patient group [PG]) and 23 healthy controls (HCs) were evaluated. Peripheric (olfactory bulb [OB] volume and olfactory sulcus [OS] depth) and central (insular gyrus and corpus amygdala areas) smell regions were measured.
Results: Smell loss was present in nine patients (39.1%) in the PG. The means of the disease duration and antiviral treatment were 3.00 ± 2.35 and 5.65 ± 1.72 days, respectively. OB volumes of the PG were significantly lower than those of the HCs bilaterally. However, no significant differences were observed between the OS depth, insular gyrus, and corpus amygdala areas of both groups. The left corpus amygdala areas were both increased with the increased disease (P = 0.035, r = 0.442) and treatment durations (P = 0.037, r = 0.438). In the PG, longer treatment duration, increase in C-reactive protein (CRP), lymphocyte count decrease, and positive thoracic computed tomography (CT) involvement were related to OS depth decrease. Right corpus amygdala areas increased in patients with COVID-19 with increased D-dimer values, and thoracic CT involvement was detected.
Conclusion: COVID-19 disease affects the peripheric smell region of OBs and does not affect the central smell regions of the insular gyrus and corpus amygdala areas. The importance of our study is to detect MRI findings in patients with COVID-19 leading to odor disorders. These findings may help in diagnosing the disease at an early stage.

Keywords: COVID-19; corpus amygdala area; insular gyrus area; olfactory bulb volume; olfactory sulcus depth.
 
Back
Top Bottom